Fosun Pharma (600196.SH) has announced that its controlling subsidiary Shanghai Henlius Biotech, Inc. and its controlled subsidiaries (collectively "Henlius") have received approval from the relevant Human Research Ethics Committee for the Phase I clinical trial protocol of HLX109 injection (an anti-IL1RAP monoclonal antibody) for the treatment of generalized pustular psoriasis, and have also completed filing with Australia's Therapeutic Goods Administration. This marks the first clinical trial authorization obtained globally for this drug.

Henlius plans to commence related clinical research for this drug in Australia once conditions are met.